Premium
PHASE 1 RESULTS OF ANTI‐PD‐LIGAND 1 (DURVALUMAB) & LENALIDOMIDE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA AND CORRELATION WITH GENE EXPRESSION PROFILE
Author(s) -
Querfeld C. S.,
Tsai N.C.,
Palmer J.,
Martinez X.,
Abdulla F.,
Wu X.,
Rosen S. T.,
Zain J.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.125_2880
Subject(s) - durvalumab , lenalidomide , medicine , immune system , immune checkpoint , oncology , immunology , cancer research , nivolumab , immunotherapy , multiple myeloma
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom